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opment, would have been welcome to complete this excellent 
review.
Dr. Vuilleumier has received research support from Roche.
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We thank Dr. Vuilleumier for his interest in our review of 
HDLs in SLE and his comments on anti–Apo A- I autoantibodies. 
Dr. Vuilleumier raises an important point, with which we fully agree, 
that the prevalence of increased levels of anti–Apo A- I is not spe-
cific to SLE. The frequency of positivity for these antibodies in 
different diseases is summarized in Table 1. Inconsistent results 
could be attributed to between- assay differences introduced 
by the use of different enzyme- linked immunosorbent assays 
 (ELISAs) and different cutoff values used to assess positivity (1).
Questions were also raised concerning whether anti–Apo 
A- I is an independent predictor of cardiovascular events in SLE 
patients. Indeed, it has not been found to be independently asso-
ciated with cardiovascular events in SLE (2,3) though, as pointed 
out by Dr. Vuilleumier, an association between anti–Apo A- I and 
cardiovascular events has been demonstrated in a broad array 
of other clinical settings (4). This inconsistency certainly warrants 
further investigation.
Dr. Vuilleumier also raised questions about our hypoth-
esis that oxidized Apo A- I may play a role in inducing anti–
Apo A- I autoantibodies. We acknowledge that the formation 
of anti–Apo A- I autoantibodies could be attributed to vari-
ous genetic and environmental factors, as he notes. At the 
same time, our hypothesis is based on our experience in the 
biopharmaceutical field, where oxidation and misfolding are 
recognized immunogenic factors for therapeutic proteins 
and peptides (5,6). In the case of Apo A- I, oxidation at Met- 
112 and Met- 148 has been suggested to cause conforma-
tional change of Apo A- I by disrupting the α- helix structure 
(7,8). Methionine oxidation on Apo A- I has also been shown 
to induce the formation of amyloid fibril, which could be 
immunogenic (9). Studies by  Henson and Venditto showed 
that Apo A- I peptide with oxidized Met- 148 could bind with 
goat polyclonal antibodies against human Apo A- 1 (10), 
and oxidized Apo A- I appeared to be more immunogenic 
in mouse models (11). In addition to methionine oxidation, 
Apo A- I could undergo other oxidative modifications, such 
as with 3- chlorotyrosine and 3- nitrotyrosine in autoimmune 
settings (12,13). Particularly, 3- nitrotyrosine modification has 
been proven to be immunogenic for other proteins and was 
suggested to be responsible for impaired immunologic tol-
erance (14). Thus, further studies on 3- chlorotyrosine– and 
3- nitrotyrosine–modified Apo A- I would be helpful to inves-
 13. Batuca JR, Amaral MC, Favas C, Paula FS, Ames PR, Papoila AL, 
et al. Extended- release niacin increases anti- apolipoprotein A- I anti-
bodies that block the antioxidant effect of high- density lipoprotein- 
cholesterol: the EXPLORE clinical trial. Br J Clin Pharmacol 
2017;83:1002–10.
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Table 1. Prevalence of anti–Apo A- I autoantibodies in different populations*
Author, year (ref.) Population Prevalence, % Positivity cutoff
Antiochos et al, 2017 (15) 5,220 participants from the general 
population (mean age 52.6 years)
19.9 97.5% of the reference distribution 
from 140 healthy blood donors
Satta et al, 2018 (16) 237 HIV patients with no current 
lipid- lowering therapy
58 97.5% of the reference distribution 
from 140 healthy blood donors
Pruijm et al, 2012 (17) 71 patients receiving maintenance 
hemodialysis
20 97.5% of the reference distribution 
from healthy blood donors
Vuilleumier et al, 2010 (18) 69 RA patients, 46 matched 
controls
17 in RA patients; 2 in healthy 
controls
97.5% of the reference distribution 
from healthy blood donors
Nigolian et al, 2020 (3) 76 patients meeting EULAR/ACR 
criteria for SLE (19)
43 97.5% of the reference distribution 
from 48 healthy donors
Butuca et al, 2007 (20) 55 SLE patients, 150 age- and 
sex-matched healthy controls
36 in SLE patients; 0.7 in 
healthy controls
>5 SD above the mean in healthy 
controls
O’Neill et al, 2010 (21) 39 SLE patients with high disease 
activity, 42 SLE patients with low 
disease activity, 34 healthy 
controls
35.9 in SLE patients with high 
activity; 12 in SLE patients 
with low activity
>3 SD above the mean in healthy 
controls
El- Lebedy et al, 2016 (22) 102 patients with type 2 DM, 112 
patients with type 2 DM and CVD, 
88 healthy controls
8.8 in patients with type 2 DM; 
35.7 in patients with both 
type 2 DM and CVD; 6.1 in 
healthy controls
Absorbance ≥2.1 OD using human 
anti–apolipoprotein AI antibody 
ELISA kit (#MBS7034; MyBioSource)
* Anti–Apo A- I = anti–aolipoprotein A- I; RA = rheumatoid arthritis; EULAR = European League Against Rheumatism; ACR = American College of 
Rheumatology; SLE = systemic lupus erythematosus; DM = diabetes mellitus; CVD = cardiovascular disease; ELISA = enzyme- linked immunosorbent 
assay. 
tigate the underlying mechanisms of anti–Apo A- I autoanti-
bodies in autoimmune settings.
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The patient, a 56- year- old woman with a history of dermatomyositis and scleroderma overlap with positive PM/Scl- 75, was admitted with 
a severe myopathy flare. The disease had been characterized by Raynaud’s phenomenon, extensive calcinosis cutis, mild interstitial lung 
disease, elevated creatine kinase level, and proximal muscle weakness. Previous treatment with methotrexate had been discontinued 
6 months prior, due to a severely infected area of calcinosis with a subsequent septic arm. Monthly intravenous immunoglobulin (IVIG) and 
low- dose prednisone were continued. Three months after finishing antibiotic treatment, the patient presented with severe dysphagia, dys-
pnea, Gottron’s papules, and weakness. Interestingly, a new lump in the posterior aspect of the left flank had been growing progressively. 
Computed tomography of the chest showed a lobulated, heterogeneous fluid collection (9.8 × 5.6 × 16.5 cm) (arrow in A) within the sub-
cutaneous soft tissue of the left lateral chest wall and extensive calcinoses covering the margins and in isolated pouches. Needle aspiration 
yielded 1 ml of white, dense matter suggestive of calcinosis. A drainage tub was surgically inserted for a week, emptying the collection. 
Cultures were negative. After 2 weeks, a stable, minimal amount of fluid (2 × 2 × 4 cm) reappeared (B). Previous calcinoses had been 
drained in the flexures, and an attempt at injecting intralesional sodium thiosulfate had been unsuccessful. Calcinosis is a common, impair-
ing manifestation of dermatomyositis and scleroderma that can appear unrelated to disease flares. No proven treatments are available. 
The myositis flare in this patient was treated with methylprednisolone boluses, IVIG, and intravenous cyclosporine and gradually improved.
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